Organicell Regenerative Medicine Inc (BPSR)

OTC Markets
0.100
0.000(0.00%)
After Hours
0.100
0.000(0.00%)
- Delayed Data
  • Volume:
    1,148,773
  • Bid/Ask:
    0.000/0.000
  • Day's Range:
    0.099 - 0.104

BPSR Overview

Prev. Close
0.1
Day's Range
0.099-0.104
Revenue
4.32M
Open
0.1
52 wk Range
0.035-0.63
EPS
-0.02
Volume
1,148,773
Market Cap
109.87M
Dividend (Yield)
N/A
(N/A)
Average Volume (3m)
6,424,771
P/E Ratio
-
Beta
7.86
1-Year Change
104.08%
Shares Outstanding
1,098,734,505
Next Earnings Date
-
What is your sentiment on Organicell Regenerative Medicine Inc?
or
Market is currently closed. Voting is open during market hours.

Organicell Regenerative Medicine Inc News

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong BuyStrong SellStrong SellStrong SellStrong Sell
Technical IndicatorsNeutralStrong SellStrong SellStrong SellSell
SummaryBuyStrong SellStrong SellStrong SellStrong Sell

Organicell Regenerative Medicine Inc Company Profile

Organicell Regenerative Medicine Inc Company Profile

Employees
18

Organicell Regenerative Medicine, Inc., a clinical-stage biopharmaceutical company, focuses on the development of biological therapeutics for the treatment of degenerative diseases. Its leading product candidate is Zofin, an acellular, biologic therapeutic derived from perinatal sources and is manufactured to retain naturally occurring microRNAs without the addition or combination of any other substance or diluent, which is in Phase I/II clinical trial to treat COVID-19. Zofin contains approximately 300 growth factors, cytokines, chemokines, and 102 unique microRNAs, as well as other exosomes/nanoparticles derived from perinatal tissues. It also provides independent education, advertising, and marketing services to medical and other healthcare, anti-aging, and regenerative service providers. Organicell Regenerative Medicine, Inc. has a research and development agreement with the Centers for Disease Control and Prevention to determine the anti-inflammatory and anti-infective effectiveness of Zofin in experimental models of influenza infection; and an agreement with Oklahoma State University to evaluate Zofin for the treatment of respiratory diseases caused by virus infections of pandemic potential. The company was formerly known as Biotech Products Services and Research, Inc. and changed its name to Organicell Regenerative Medicine, Inc. in June 2018. Organicell Regenerative Medicine, Inc. was founded in 2011 and is headquartered in Miami, Florida.

Read More
    Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
    Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.